Data from the Phase II/III DEVOTE trial demonstrated that SPINRAZA demonstrated significant improvements in motor function at six months in infants with spinal muscular atrophy.
High-dose SPINRAZA significantly improves motor function in infants with spinal muscular atrophy
Leave a comment
